NTLA logo

ARKG Holdings of NTLA

Intellia Therapeutics

Intellia Therapeutics is a biotechnology company focused on the development of therapies using CRISPR/Cas9 gene-editing technology to potentially treat genetic diseases. The company generates revenue through partnerships, collaborations, and the development of proprietary treatments aimed at commercializing innovative gene-editing solutions.

Trades of NTLA in ARKG

The ten most recent trades of Intellia Therapeutics in the ARKG ETF.View all trades

Date
Direction
Market Value
% of Position
% of ETF
Jan 10, 2025Buy$443,2521.42%0.04%
Jan 08, 2025Buy$306,6710.88%0.03%
Dec 20, 2024Buy$365,4231.05%0.04%
Dec 18, 2024Buy$307,7510.86%0.03%
Dec 16, 2024Buy$321,1190.86%0.03%
Dec 13, 2024Buy$91,8420.25%0.01%
Nov 19, 2024Buy$830,1882.15%0.07%
Nov 15, 2024Buy$123,7910.31%0.01%
Oct 24, 2024Buy$625,5661.40%0.05%
Oct 18, 2024Buy$610,9181.07%0.05%